Starting highly active antiretroviral therapy: Why, when and response to HAART

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 1, 2004, Pages 10-13

  Mocroft, Amanda ^a   Lundgren, Jens D ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

HIV infection; Outcomes; Treatments

Indexed keywords

NUCLEOSIDE ANALOG;

ANTIBIOTIC RESISTANCE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; IMMUNE DEFICIENCY; LIVER TOXICITY; LONG TERM CARE; NONHUMAN; PROGNOSIS; RISK REDUCTION; VIRUS DETECTION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 3543113213     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh290     Document Type: Article

References (23)

1. Mocroft, A., Vella, S., Benfield, T. L. et al. (1998). Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352, 1725-30.
2. Panel on Clinical Practices for Treatment of HIV Infection (2004). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. [Online.] http://aidsinfo.nih.gov/guidelines/ (29 March 2004, date last accessed).
3. The PLATO collaboration (2004). Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (in press).
4. Carpenter, C. C. J., Fischl, M. A., Hammer, S. M. et al. (1996). Antiretroviral therapy for HIV in 1996: recommendations of an international panel. Journal of the American Medical Association 276, 146-54.
5. Phillips, A. N., Cozzi Lepri, A., Lampe, F. et al. (2003). When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 17, 1863-9.
6. Emery, S., Abrams, D. I., Cooper, D. A. et al. (2002). ESPRIT Study Group. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Controlled Clinical Trials 23, 198-220.
7. John, M., Moore, C., James, I. et al. (2001). Chronic hyperlactaemia in HIV-infected patients taking antiretroviral therapy. AIDS 15, 717-23.
8. Wit, F. W., Weverling, G. J., Weel, J. et al. (2002). Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. Journal of Infectious Diseases 186, 22-31.
9. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group (2003). Combination antiretroviral therapy and risk of myocardial infarction. New England Journal of Medicine 349, 1993-2003.
10. Gullick, R. M., Mellors, J. M., Havlir, D. et al. (1997). Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 337, 734-9.
11. Madge, S., Mocroft, A., Wilson, D. et al. (2000). Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Medicine 4, 212-8.
12. Ledergerber, B., Egger, M., Opravil, M. et al. (1999). Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 353, 863-8.
13. Nieuwkerk, P. T., Sprangers, M. A. G., Burger, D. M. et al. (2001). Limited patients adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Archives of Internal Medicine 161, 1962-8.
14. Ickovics, J. R., Camerop, A., Zackin, R. et al. (2002). Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antiviral Therapy 7, 185-93.
15. Paredes, R., Mocroft, A., Kirk, O. et al. (2000). Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy. Archives of Internal Medicine 160, 1123-32.
16. Cozzi Lepri, A., Miller, V., Phillips, A. N. et al. (2001). The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. AIDS 15, 47-54.
17. Mocroft, A., Devereaux, H., Kinloch-de-Loes, S. et al. (2000). Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS 14, 1545-52.
18. Viard, J. P., Mocroft, A., Chiesi, A. et al. (2001). Influence of age on CD4 cell recovery in human immunodeficiency virus infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. Journal of Infectious Diseases 183, 1290-4.
19. Egger, M., May, M., Chene, G. et al. (2002). Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360, 119-29.
20. Palella, F. J., Deloria-Knoll, M., Chmiel, J. S. et al. (2003). Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Annals of Internal Medicine 138, 620-6.
21. Hogg, R. S., Yip, B., Chan, K. J. et al. (2001). Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. Journal of the American Medical Association 286, 2568-77.
22. O'Brien, M. E., Clark, R. A., Besch, L. et al. (2003). Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. Journal of Acquired Immune Deficiency Syndromes 34, 407-14.
23. Sterling, T. R., Chaisson, R. E. & Moore, R. D. (2001). HIV-1 RNA CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 15, 2251-7.